edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Actinogen Medical
Edison Investment Research has terminated coverage on Actinogen Medical (ACW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Actinogen Medical — 7 videos in collection
Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. Primary indication is cognitive impairment in mild AD patients and results from the ongoing Phase II XanADu trial are expected to be announced in Q219. In this video, the company’s chief executive officer Bill Ketelbey introduces the company and lead asset, and provides an overview of R&D progress and expected news flow.
Get access to the very latest content matched to your personal investment style.